Why Nektar Therapeutics May Be About to Take Off
Don't just ask, "How much inventory?" Ask, "What kind?"
Here's What Seth Klarman Is Buying
See what the smartest investors have been up to.
Biotech Analysts See Buying Opportunities From Sell-Off
We compiled a list of biotech companies that have underperformed the S&P 500 over the last month but maintain a solid list of fundamentals.
7 Biotechs Near 52-Week Lows
Trolling the bottom for upside potential.